DNA PROBES-BASED DIAGNOSTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for DNA Probes-based Diagnostics in US$ Million by the following Application Areas: Infectious Diseases, Cancer Testing, Genetic Predisposition, Identity/Forensics, Molecular HLA (Human Leukocyte Antigen) Typing, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain. The report profiles 63 companies including many key and niche players such as -

Abbott Laboratories
Affymetrix, Inc.
Becton
Dickinson & Company
Beckman Coulter, Inc.
bioMérieux


Click here to request a full list of companies covered in the report...

Code : MCP-3405
Price : $4200
Companies : 63
Pages : 474
Date : May 2012
Market Data Tables : 57

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Infectious Diseases.....I-3
  
   Cancer.....I-4
Genetic Predisposition.....I-4
Identity/Forensics.....I-4
Molecular HLA Testing.....I-4
Other Diagnostic Applications.....I-4
  
   Industry Overview.....II-1
DNA Probes: Robust Growth Ahead.....II-1
Decoding the Genetic Puzzle.....II-1
1$100
   Advantages of DNA-Probe Tests.....II-2
Growth Drivers in a Nutshell.....II-2
Growth Inhibitors in a Nutshell.....II-2
1$100
   Genetic Profiling of Pathogens: A Road Less Traveled.....II-3
Roche’s Entry into the Hall of Molecular Fame.....II-3
DNA Technology: An Evolutionary Scan.....II-3
1$100
   An Era of Excellence: Tracking Landmark Breakthroughs in DNA Diagnostics.....II-41$100
   Opportunities.....II-51$100
   Market Trends/Issues.....II-6
DNA Tests: Finding Use in Numerous Applications.....II-6
World’s Aging Population Drives the Popularity of DNA-Probe Tests.....II-6
Reimbursements: “Under the Umbrella”.....II-6
Evolution of New & Virulent Infectious Agents.....II-6
1$100
   The Enlightened Consumer of the 21st Century.....II-7
Challenges In Widespread Deployment of DNA Based Diagnostics.....II-7
Miniaturization: An Uphill Task.....II-7
Improvements in Assay Capabilities.....II-7
1$100
   Information Handling & Processing: The Soft Side of Diagnostics.....II-8
Integration: The Ultimate Challenge.....II-8
The United States: Unraveling the Country’s Edge in DNA based Diagnostics.....II-8
1$100
   Diagnostic Gene Detection Products.....II-9
Molecular Diagnostics: A Powerful Disease Detection Tool.....II-9
1$100
   DNA Probes-Based Products.....II-10
Direct Detection of Target Sequence.....II-10
Nucleic Acid Amplification.....II-10
Gene Detection Using DNA Chips.....II-10
Gene Detection by DNA Sequencing.....II-10
1$100
   The Dynamics of Key Enabling Technologies.....II-11
In Situ Hybridization.....II-11
PCR: Polymerase Chain Reaction.....II-11
Chemiluminescence.....II-11
1$100
   Gen-Probe Tigris.....II-12
DNA Chips.....II-12
Key Players.....II-12
Players in Molecular Diagnostics Market.....II-12
Molecular Diagnostics - A Primer.....II-12
1$100
   Implications for Clinical Diagnostics.....II-13
Need of the Hour.....II-13
Molecular Diagnostics: Marking the Convergence of Numerous Technologies.....II-13
Impact of the Human Genome Project.....II-13
1$100
   Molecular Diagnostics: Domain of the Developed Countries.....II-14
“Tailored Patient Management”: An Epitomized Future of Molecular Diagnostics.....II-14
Futuristics: A Rumination.....II-14
1$100
   Background.....II-15
Gene Probe Technology.....II-15
What is DNA?.....II-15
DNA Probes.....II-15
1$100
   Miniaturization: A Revolutionary Method in DNA Analysis.....II-16
Gene Chip Technology.....II-16
DNA Chips.....II-16
Chromosome Painting Probes.....II-16
1$100
   Diagnostic Applications Based on DNA Probes: An Overview.....II-17
Infectious Diseases.....II-17
Respiratory Tract Infections.....II-17
Diagnosis of Mycoplasma.....II-17
DNA Probes to Detect Legionella Pneumophila.....II-17
Detecting Tuberculosis Through Rapid Diagnostic Tests.....II-17
1$100
   How the Technique Works.....II-18
Limitations.....II-18
Sexually Transmitted Diseases (STDs).....II-18
HIV.....II-18
HTLV-1 Testing.....II-18
Hepatitis Testing.....II-18
1$100
   Chlamydia DNA Probes.....II-19
Detection of Intestinal Parasites.....II-19
Entamoeba Histolytica.....II-19
Salmonella.....II-19
Identity/Forensics.....II-19
DNA Profiling: A Key Forensic Tool.....II-19
1$100
   DNA-Based Forensic Diagnostics.....II-20
Tracing Human Origins.....II-20
Genetic Predisposition.....II-20
Molecular HLA Testing.....II-20
Human Leukocyte Antigen (HLA) Typing.....II-20
1$100
   Cancer Testing.....II-21
Cancer: A Deadly Disease Afflicting Millions.....II-21
Slow Detoxifiers: Potential Cancer Candidates.....II-21
Improving Cancer Surgery Through Diagnostic Tests.....II-21
Types of Cancer.....II-21
Chronic Lymphocytic Leukemia (CLL).....II-21
1$100
   Breast Cancer.....II-22
PCR Screening Technology for Breast Cancer.....II-22
Eye Cancers.....II-22
DNA Probes to Detect Retinoblastoma.....II-22
Others.....II-22
The Ames test.....II-22
1$100
   Genetic Testing.....II-23
Other Diagnostic Applications.....II-23
Cystic Fibrosis.....II-23
Malaria Testing.....II-23
1$100
   Detection of Multidrug Resistance.....II-24
Bacterial Resistance to Antibiotics.....II-24
DNA Probes for Agriculture.....II-24
1$100
   LifeTechnologies Launches Applied Biosystems AutoMate Express™.....II-25
OralDNA Labs™ Launches Two Dental Molecular Tests.....II-25
1$100
   Luminex Molecular Introduces New xTAG™ Respiratory Viral Panel.....II-26
Gen-Probe Introduces Aptima HPV Assay in Europe.....II-26
Genzyme Genetics Introduces Prenatal Diagnosis and Carrier Testing.....II-26
1$100
   Affymetrix Launches New Cytogenetic Solution.....II-27
Genekam Biotech Develops New Commercial DNA-Test to Detect Bird Flu.....II-27
Seegene Launches Innovative DNA Test to Detect HPVs.....II-27
1$100
   deCODE Introduces deCODE T2.....II-28
InterGenetics Introduces OncoVue.....II-28
bioMérieux Unveils VIDAS C.....II-28
bioMérieux Unveils NucliSENS EasyQ HPV.....II-28
1$100
   Applied Biosystems Launches SOLiD System.....II-29
bioMérieux Introduces VIDAS® NT-proBNP.....II-29
Abbott Molecular Rolls Out Six DNA Probes.....II-29
1$100
   PerkinElmer Launches Two New Multiplexing Platforms for Genomic Research.....II-30
Kreatech Introduces First Complete Whole Genome Amplification Kit.....II-30
1$100
   Relative Genetics Introduces DNA Testing Services.....II-31
Sorenson Launches Over-the-counter Paternity Test Kits.....II-31
Kimball Genetics Introduces Warfarin Sensitivity DNA Test.....II-31
1$100
   bioMérieux Introduces TEMPO EB.....II-32
Gen-Probe Launches PCA3 Assay.....II-32
Genzyme Launches New KRAS Mutation Analysis.....II-32
BD Launches New BD Viper™ System for Automating Molecular Diagnostic Testing
  Process.....II-32
1$100
   Affymetrix Unveils New GeneChip® Scanner with Higher Capacity Scanning.....II-33
Genzyme Introduces EGFR Mutation Assay for Detecting Mutations.....II-33
1$100
   Danaher Acquires Beckman Coulter.....II-34
QIAGEN Partners with Genome Diagnostics.....II-34
ZyGEM Snaps Up MicroLab Diagnostics.....II-34
1$100
   Metropolis Healthcare Partners with DDC.....II-35
China Medical Technologies Obtains SFDA Approval.....II-35
Nanobac Inks Merger Agreement with Eureka Genomics.....II-35
Genzyme Enters into Licensing Agreement with Moffitt Cancer Center.....II-35
1$100
   Xceed Molecular Offers Gen-Probe License for Flow-Thru Chip® Technology.....II-36
Dako Denmark’s TOP2A FISH pharmDx Receives FDA Approval.....II-36
Roche Diagnostics Receives Approval for Elecsys Anti-HCV Assay.....II-36
1$100
   bioMérieux and FIND Ink Memorandum of Understanding.....II-37
BD Establishes Second Production Facility in China.....II-37
Shanghai Kehua Bio-engineering and bioMérieux Establish Joint Venture.....II-37
1$100
   Quidel to Enter into Alliance with bioMérieux.....II-38
Beckman Coulter Bags Rights to Hepatitis C Virus Test from Siemens.....II-38
Affymetrix Enters into Partnership with Pathwork Diagnostics.....II-38
1$100
   Luminex Signs Distribution and Sales Agreement with Abbott.....II-39
Gen-Probe to Acquire Innogenetics.....II-39
1$100
   Biocept to Introduce I.D.Rh(D).....II-40
DNA Testing Systems and DNAPrint Genomics Sign Sales Agreement.....II-40
1$100
   Siemens Acquires Dade Behring.....II-41
Sorenson Genomics Acquires Identigene.....II-41
BioServe Takes Over Genomics Collaborative.....II-41
1$100
   Illumina Acquires Solexa.....II-42
QIAGEN to Merge With eGene.....II-42
NorDiag Acquires Genpoint.....II-42
Cepheid Takes Over Sangtec Molecular Diagnostics.....II-42
1$100
   3M Enters into Collaboration with Gen-Probe.....II-43
Luminex Corporation Completes Acquisition of Tm Bioscience.....II-43
1$100
   Ventana Medical Systems and C-Path to Collaborate with NCI and FDA.....II-44
Ipsen and bioMérieux Enter into Theragnostics Agreement.....II-44
1$100
   Celera Acquires Atria Genetics.....II-45
Celera Acquires Berkeley HeartLab.....II-45
Beckman Coulter Enters into Partnership.....II-45
Affymetrix Partners with IPSOGEN for In-Vitro Diagnostic Cancer Testing.....II-45
1$100
   Ventana Medical Systems Collaborates with Genentech.....II-46
Siemens Medical Solutions Acquires Bayer’s Diagnostic Division.....II-46
1$100
   Orchid Cellmark Acquires ReliaGene Technologies.....II-47
GATC Enters into Collaboration for Developing DNA-based Diagnostic Test.....II-47
Genetic Solutions and Catapult Merge to Establish Catapult Genetics.....II-47
1$100
   Grant Life Sciences Signs MoU with Alphagenics Diaco Biotechnologies.....II-48
Gen-Probe and Millipore Ink Agreement to Market MTC-NI Test.....II-48
1$100
   QIAGEN Acquires Digene Corporation.....II-49
BD Diagnostics and Quest Diagnostics Sign Agreement for BD Viper™ System.....II-49
Enzo Biochem Plans to Produce Single Copy DNA Probes.....II-49
1$100
   Affymetrix Signs Two Agreements with Sysmex.....II-50
Affymetrix and Partners HealthCare Enter into Collaboration.....II-50
Affymetrix and Epigenomics Enter into an Agreement.....II-50
1$100
   Roche Introduces Elecsys TORCH Assays.....II-51
QIAGEN to Take Over Gentra.....II-51
LGC Acquires AGOWA to Extend German Operations.....II-51
1$100
   ENZ Receives Patent for Phosphate Labeling for Medical Research & DNA Diagnostic
  Products.....II-52
TMC Achieves CE Mark for its Tag-It Cystic Fibrosis Test Kit.....II-52
Toshiba Licenses Electrochemical Detection Technology to Antara.....II-52
1$100
   Affymetrix Licenses Multiple Patents to Invitrogen.....II-53
Abbott Enters into Agreement with ALSI for Licensing ProGRP Biomarker.....II-53
QIAGEN in Protein Crystallography Co-Marketing Agreement with ActiveSight.....II-53
1$100
   Warnex Acquires Pro-DNA Diagnostic.....II-54
Celera Genomics Gains Complete Ownership of Celera Diagnostics.....II-54
Gen-Probe Licenses Exclusive Rights for Diagnostic Tests Development from University of
  Michigan.....II-54
1$100
   QIAGEN Enters into Licensing Agreement with Applied Biosystems for Real-Time PCR
  Technologies.....II-55
IGC Collaborates with Roche for Cancer Biomarker Discovery.....II-55
Affymetrix Acquires ParAllele BioScience.....II-55
QIAGEN Enters into Distribution Agreement with Osmetech Molecular Diagnostics.....II-55
1$100
   GlaxoSmithKline Acquires Canada-Based ID Biomedical Corp......II-56
Gen-Probe Obtains FDA Approval for Marketing APTIMA.....II-56
Gen-Probe Signs Purchasing Agreement with Roche.....II-56
MP Biomedicals Acquires Qbiogene.....II-56
Roche Diagnostics Receives FDA Approval for AmpliChip CYP450 Test.....II-56
1$100
   Ventana Launches ISH Tests.....II-571$100
   Abbott Molecular (US).....II-58
Affymetrix, Inc. (US).....II-58
Becton, Dickinson & Company (US).....II-58
1$100
   Beckman Coulter, Inc. (US).....II-59
bioMérieux (France).....II-59
Celera Group (US).....II-59
Gen-Probe Incorporated (US).....II-59
1$100
   Genzyme Corporation (US).....II-60
Luminex Molecular Diagnostics (Canada).....II-60
QIAGEN (US).....II-60
Roche Diagnostics (Switzerland).....II-60
1$100
   Siemens Healthcare Diagnostics, Inc. (US).....II-611$100
   Table 1: World Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-621$350
   Table 2: World Historic Review for DNA Probes-based Diagnostics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-631$350
   Table 3: World 15-Year Perspective for DNA Probes- based Diagnostics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-641$350
   Table 4: World Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics (Infectious Disease Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-651$350
   Table 5: World Historic Review for DNA Probes-based Diagnostics (Infectious Disease Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-661$350
   Table 6: World 15-Year Perspective for DNA Probes- based Diagnostics (Infectious Disease Diagnosis) by Geographic Region – Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-671$350
   Table 7: World Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics (Cancer Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-681$350
   Table 8: World Historic Review for DNA Probes-based Diagnostics (Cancer Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-691$350
   Table 9: World 15-Year Perspective for DNA Probes- based Diagnostics (Cancer Diagnosis) by Geographic Region – Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-701$350
   Table 10: World Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics (Genetic Predisposition Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-711$350
   Table 11: World Historic Review for DNA Probes- based Diagnostics (Genetic Predisposition Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin American Markets Independently Analyzed with Annual Revenue Figures Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-721$350
   Table 12: World 15-Year Perspective for DNA Probes- based Diagnostics (Genetic Predisposition Diagnosis) by Geographic Region – Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-731$350
   Table 13: World Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics (Identity/Forensics Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-741$350
   Table 14: World Historic Review for DNA Probes- based Diagnostics (Identity/Forensics Diagnosis) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-751$350
   Table 15: World 15-Year Perspective for DNA Probes-based Diagnostics (Identity/Forensics Diagnosis) by Geographic Region – Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-761$350
   Table 16: World Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics (Molecular HLA Testing) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-771$350
   Table 17: World Historic Review for DNA Probes-based Diagnostics (Molecular HLA Testing) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-781$350
   Table 18: World 15-Year Perspective for DNA Probes- based Diagnostics (Molecular HLA) by Geographic Region – Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-791$350
   Table 19: World Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics in Others Types of Diagnosis by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-801$350
   Table 20: World Historic Review for DNA Probes-based Diagnostics in Others Types of Diagnosis by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin American Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-811$350
   Table 21: World 15-Year Perspective for DNA Probes- based Diagnostics in Others Types of Diagnosis by Geographic Region – Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Latin American Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-821$350
   A. Market Analysis.....III-1
DNA-Based Diagnostic and Test Market: Progress towards a New Phase.....III-1
DNA-Based Diagnostic Tests Picks Up Pace in New Streams.....III-1
1$75
   Rise of DNA-Based Home Testing Kits Market.....III-2
Focus on Select Key Players.....III-2
1$75
   B. Market Analytics.....III-3
Table 22: The US Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-3
1$200
   Table 23: The US Historic Review for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity / Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-41$200
   Table 24: The US 15-Year Perspective for DNA Probes- based Diagnostics by Application Area Percentage Breakdown of Revenues for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-51$200
   Market Analytics.....III-6
Table 25: Canadian Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-6
1$200
   Table 26: Canadian Historic Review for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity /Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-71$200
   Table 27: Canadian 15-Year Perspective for DNA Probes-based Diagnostics by Application Area Percentage Breakdown of Revenues for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Marketsfor Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-81$200
   Market Analytics.....III-9
Table 28: Japanese Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-9
1$200
   Table 29: Japanese Historic Review for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/ Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-101$200
   Table 30: Japanese 15-Year Perspective for DNA Probes-based Diagnostics by Application Area Percentage Breakdown of Revenues for Infectious Diseases,Cancer, Genetic Predisposition, Identity/ Forensics, Molecular HLA Testing, and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-111$200
   Market Analytics.....III-12
Table 31: European Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-12
1$200
   Table 32: European Historic Review for DNA Probes- based Diagnostics by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-131$200
   Table 33: European 15-Year Perspective for DNA Probes-based Diagnostics by Geographic Region – Percentage Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-141$200
   Table 34: European Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-151$200
   Table 35: European Historic Review for DNA Probes- based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-161$200
   Table 36: European 15-Year Perspective for DNA Probes-based Diagnostics by Application Area Percentage Breakdown of Revenues for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-171$200
   Market Analytics.....III-18
Table 37: French Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-18
1$200
   Table 38: French Historic Review for DNA Probes- based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/ Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-191$200
   Table 39: French 15-Year Perspective for DNA Probes- based Diagnostics by Application Area Percentage Breakdown of Revenues for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2011 & 2017 (includes correspondingGraph/Chart).....III-201$200
   Market Analytics.....III-21
Table 40: German Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-21
1$200
   Table 41: German Historic Review for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-221$200
   Table 42: German 15-Year Perspective for DNA Probes-based Diagnostics by Application Area Percentage Breakdown of Revenues for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-231$200
   Market Analytics.....III-24
Table 43: Italian Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-24
1$200
   Table 44: Italian Historic Review for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity / Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-251$200
   Table 45: Italian 15-Year Perspective for DNA Probes-based Diagnostics by Application Area – Percentage Breakdown of Revenues for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-261$200
   Market Analytics.....III-27
Table 46: The UK Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-27
1$200
   Table 47: The UK Historic Review for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-281$200
   Table 48: The UK 15-Year Perspective for DNA Probes-based Diagnostics by Application Area – Percentage Breakdown of Revenues for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-291$200
   Market Analytics.....III-30
Table 49: Rest of European Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-30
1$200
   Table 50: Rest of European Historic Review for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/ Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-311$200
   Table 51: Rest of European 15-Year Perspective for DNA Probes-based Diagnostics by Application Area – Percentage Breakdown of Revenues for Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-321$200
   Market Analytics.....III-33
Table 52: Asia-Pacific Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-33
1$200
   Table 53: Asia-Pacific Historic Review for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-341$200
   Table 54: Asia-Pacific 15-Year Perspective for DNA Probes-based Diagnostics by Application Area – Percentage Breakdown of Revenues for Infectious Diseases, Cancer, Genetic Predisposition, dentity/ Forensics, Molecular HLA Testing, and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-351$200
   Market Analytics.....III-36
Table 55: Latin American Recent Past, Current & Future Analysis for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-36
1$200
   Table 56: Latin American Historic Review for DNA Probes-based Diagnostics by Application Area – Infectious Diseases, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-371$200
   Table 57: Latin American 15-Year Perspective for DNA Probes-based Diagnostics by Application Area – Percentage Breakdown of Revenues for Infectious Diseases, Cancer, Genetic Predisposition, dentity/ Forensics, Molecular HLA Testing, and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-381$200
  
Total Companies Profiled: 63 (including Divisions/Subsidiaries - 79)

Region/Country Players

The United States 51 Canada 6 Japan 2 Europe 18 France 1 Germany 8 The United Kingdom 3 Italy 1 Rest of Europe 5 Asia-Pacific (Excluding Japan) 2
Click here to request a full table of contents and more details on this project.